Literature DB >> 12593858

Activation of phospholipase D1 by ADP-ribosylated RhoA.

Harald Genth1, Martina Schmidt, Ralf Gerhard, Klaus Aktories, Ingo Just.   

Abstract

Clostridium botulinum exoenzyme C3 exclusively ADP-ribosylates RhoA, B, and C to inactivate them, resulting in disaggregation of the actin filaments in intact cells. The ADP-ribose resides at Asn-41 in the effector binding region, leading to the notion that ADP-ribosylation inactivates Rho by blocking coupling of Rho to its downstream effectors. In a recombinant system, however, ADP-ribosylated Rho bound to effector proteins such as phospholipase D-1 (PLD1), Rho-kinase (ROK), and rhotekin. The ADP-ribose rather mediated binding of Rho-GDP to PLD1. ADP-ribosylation of Rho-GDP followed by GTP-gamma-S loading resulted in binding but not in PLD activation. On the other hand, ADP-ribosylation of Rho previously activated by binding to GTP-gamma-S resulted in full PLD activation. This finding indicates that ADP-ribosylation seems to prevent GTP-induced change to the active conformation of switch I, the prerequisite of Rho-PLD interaction. In contrast to recombinant systems, ADP-ribosylation in intact cells results in functional inactivation of Rho, indicating other mechanisms of inactivation than blocking effector coupling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12593858     DOI: 10.1016/s0006-291x(03)00112-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Inhibition of macrophage migration by C. botulinum exoenzyme C3.

Authors:  Jacqueline Rotsch; Astrid Rohrbeck; Martin May; Tanja Kolbe; Sandra Hagemann; Ilona Schelle; Ingo Just; Harald Genth; Stefanie C Huelsenbeck
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-29       Impact factor: 3.000

Review 2.  C3 exoenzymes, novel insights into structure and action of Rho-ADP-ribosylating toxins.

Authors:  Martin Vogelsgesang; Alexander Pautsch; Klaus Aktories
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-12-05       Impact factor: 3.000

3.  The Staphylococcus aureus epidermal cell differentiation inhibitor toxin promotes formation of infection foci in a mouse model of bacteremia.

Authors:  Patrick Munro; Maxime Benchetrit; Marie-Anne Nahori; Caroline Stefani; René Clément; Jean-François Michiels; Luce Landraud; Olivier Dussurget; Emmanuel Lemichez
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

4.  Structural basis for the NAD-hydrolysis mechanism and the ARTT-loop plasticity of C3 exoenzymes.

Authors:  Julie Ménétrey; Gilles Flatau; Patrice Boquet; André Ménez; Enrico A Stura
Journal:  Protein Sci       Date:  2008-03-27       Impact factor: 6.725

Review 5.  Novel bacterial ADP-ribosylating toxins: structure and function.

Authors:  Nathan C Simon; Klaus Aktories; Joseph T Barbieri
Journal:  Nat Rev Microbiol       Date:  2014-07-14       Impact factor: 60.633

Review 6.  Bacterial protein toxins that modify host regulatory GTPases.

Authors:  Klaus Aktories
Journal:  Nat Rev Microbiol       Date:  2011-06-16       Impact factor: 60.633

7.  Crystal structure of mouse RhoA:GTPγS complex in a centered lattice.

Authors:  Chacko Jobichen; Kuntal Pal; Kunchithapadam Swaminathan
Journal:  J Struct Funct Genomics       Date:  2012-09-22

Review 8.  Bacterial factors exploit eukaryotic Rho GTPase signaling cascades to promote invasion and proliferation within their host.

Authors:  Michel R Popoff
Journal:  Small GTPases       Date:  2014-05-08

9.  Clostridium difficile toxin B differentially affects GPCR-stimulated Ca2+ responses in macrophages: independent roles for Rho and PLA2.

Authors:  Robert A Rebres; Christina Moon; Dianne Decamp; Keng-Mean Lin; Iain D Fraser; Stephen B Milne; Tamara I A Roach; H Alex Brown; William E Seaman
Journal:  J Leukoc Biol       Date:  2010-03-03       Impact factor: 4.962

Review 10.  Therapeutic effects of Clostridium botulinum C3 exoenzyme.

Authors:  Ingo Just; Astrid Rohrbeck; Stefanie C Huelsenbeck; Markus Hoeltje
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-12-31       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.